Global Plasma Fractionation Market Size study & Forecast, by Product ( Albumin, Immunoglobulins, Coagulation Factors, Protease Inhibitors, Others), by Method (Centrifugation, Depth Filtration, Chromatography, Others)by Application (Neurology, Hematology,

Global Plasma Fractionation Market Size study & Forecast, by Product ( Albumin, Immunoglobulins, Coagulation Factors, Protease Inhibitors, Others), by Method (Centrifugation, Depth Filtration, Chromatography, Others)by Application (Neurology, Hematology, Oncology, Immunology, Pulmonology, Others), by End User(Hospitals & Clinics, Clinical Research, Others) and Regional Analysis, 2023-2030

Global Plasma Fractionation Market is valued approximately USD 30.87 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 8.3% over the forecast period 2023-2030. Plasma fractionation is a process used to separate different components of blood plasma, such as proteins and other bioactive substances. Blood plasma is the liquid component of blood that remains after red blood cells, white blood cells, and platelets have been removed. Plasma fractionation plays a vital role in the production of various therapeutic products, including immunoglobulins, albumin, clotting factors, and other specialized plasma-derived products. These products are used for treating a wide range of medical conditions, such as immune deficiencies, hemophilia, clotting disorders, and certain neurological diseases. The Plasma Fractionation market is expanding because of factors such as growing incidences of immunodeficiency disorders, surge in demand for plasma derived medicinal products and growing geriatric population.

Worldwide, there has been a significant increase in demand for plasma-derived medicines. Strong growth in immunoglobulin demand resulted in positive market expansion on a global scale. The increase in incidence of various immunodeficiency illnesses around the world is the cause of the rising demand. Immunoglobulin substitution therapy or specialized immunoglobulin therapies can be used to treat such illnesses. As a result, the market is driven by the rising demand for these therapies and the consequent growth in immunoglobulin synthesis by these techniques according to UNAIDS, 37.7 million people globally faced Human Immunodeficiency Virus (HIV) in 2020. Along with these, according to The Centres for Disease Control and Prevention (CDC) in the United States in 2021, there were between 3,000 and 6,000 people have the Guillain-Barré Syndrome. The U.S. Food and Drug Administration (FDA) has approved IVIG for use in children with HIV in order to reduce the risk of bacterial infections. The demand for plasma-derived therapies increased as a result of the increasing frequency of various immunodeficiency disorders and other diseases, which aided in the expansion of the global market. In addition, adoption of Plasma Proteins in immunology & neurology procedures and increasing R&D projects involving plasma treatments. The successful launch of this product may provide patients with an alternative option is creating lucrative growth to the market. However, the high cost of plasma fractionation and emergence of recombinant therapies as an alternative to plasma derived medicines stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Plasma Fractionation Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the dominance of branded products and the region's increasing disease prevalence. Asia Pacific is expected to grow significantly during the forecast period, owing to factors such as rising geriatric and target populations, an increase in the number of collaborations for product development, geographic expansion of key players, and active participation of government and nonprofit organizations in the market space.

Major market player included in this report are:
Grifols S.A.
CSL Limited
Takeda Pharmaceutical Company Limited
Octapharma AG
Kedrion S.p.A
LFB S.A.
Biotest AG
Sanquin
Bio Products Laboratory Ltd.
Intas Pharmaceuticals Ltd

Recent Developments in the Market:
In January 2022, Octapharma AG released information regarding the subcutaneous human immunoglobulin cutaquig, its indication has recently been expanded by the European Union (EU). The expansion would provide patients with acquired immune deficiencies with more diverse treatment options.

In June 2021, LFB Plasma has acquired ImmunoTek Bio Centre. A reliable and continuous supply of plasma will be available in the United States due to the acquisition of the plasma collection facility.

Global Plasma Fractionation Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered - Product, Method, Application, End User, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Product:
Albumin
Immunoglobulins
Coagulation Factors
Protease Inhibitors
Others

By Method:
Centrifugation
Depth Filtration
Chromatography
Others

By Application:
Neurology
Hematology
Oncology
Immunology
Pulmonology
Others

By End User:
Hospitals & Clinics
Clinical Research
Others

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
Grifols S.A.
CSL Limited
Takeda Pharmaceutical Company Limited
Octapharma AG
Kedrion S.p.A
LFB S.A.
Biotest AG
Sanquin
Bio Products Laboratory Ltd.
Intas Pharmaceuticals Ltd

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.